Intracellular pH (pHi) is a fundamental parameter to cell function that requires tight homeostasis [1]. In the absence of any regulation, the cytosol would have the tendency to become acidiﬁed due to the continuous buildup of metabolic acid (H+ ) equivalents [2, 3]. Cells have developed means to raise cytosolic pH, guarding against dangerous acidiﬁcation. Regulation of pHi comprises several processes such as cytosolic H+ buffering, H+ sequestration into cellular organelles, and transmembrane movement of acid equivalents [1, 3, 4]. Cells regulate rapid and localized pH swings by their intrinsic pH buffering capacity which is provided by several intracellular weak acids and bases. Moreover, cells regulate pH through the bicarbonate (HCO3−) buffer system which combines with excess H+ ions to form carbonic acid [5]. Then, carbonic acid is transformed to carbon dioxide (CO2) by the enzyme carbonic anhydrase [5]. The total buffer capacity includes both components [1, 2, 4]. Although effective this buffering system has limited capacity to counteract continuous generation of H+ equivalents by metabolism, ongoing transport of ions that alter the pH (H+ and HCO3−), or the presence of diseases that contribute to extracellular acidiﬁcation (inflammation, hypoxia, or ischemia). The mechanism of regulation of pHi carried out by transporters requires energy as H+ is transported against its electrochemical gradient. Thus, transporters use the inward Na+ gradient produced by the 3Na+/2K+-ATPase. Several proteins carry out this function being one of the most important Na+/H+ exchangers [1, 6, 7].

Mammalian Na+/H+ exchangers (NHEs) are electroneutral Na+-dependent proteins that exchange extracellular Na+ for intracellular H+. To date, there are 9 identiﬁed NHE isoforms where NHE1 is the most ubiquitous member, known as the housekeeping exchanger. NHE1 seems to have a protective role in the ischemia-reperfusion injury and other inﬂammatory diseases. In nociception, NHE1 is found in neurons along nociceptive pathways, and its pharmacological inhibition increases nociceptive behavior in acute pain models at peripheral and central levels. Electrophysiological studies also show that NHE modulates electrical activity of primary nociceptive terminals. However, its role in neuropathic pain still remains controversial. In humans, NHE1 may be responsible for inflammatory bowel diseases since its expression is reduced in Crohn’s disease and ulcerative colitis. The purpose of this work is to provide a review of the evidence about participation of NHE1 in the nociceptive processing.

1. Introduction

Intracellular pH (pHi) is a fundamental parameter to cell function that requires tight homeostasis [1]. In the absence of any regulation, the cytosol would have the tendency to become acidiﬁed due to the continuous buildup of metabolic acid (H+ ) equivalents [2, 3]. Cells have developed means to raise cytosolic pH, guarding against dangerous acidiﬁcation. Regulation of pHi comprises several processes such as cytosolic H+ buffering, H+ sequestration into cellular organelles, and transmembrane movement of acid equivalents [1, 3, 4]. Cells regulate rapid and localized pH swings by their intrinsic pH buffering capacity which is provided by several intracellular weak acids and bases. Moreover, cells regulate pH through the bicarbonate (HCO3−) buffer system which combines with excess H+ ions to form carbonic acid [5]. Then, carbonic acid is transformed to carbon dioxide (CO2) by the enzyme carbonic anhydrase [5]. The total buffer capacity includes both components [1, 2, 4]. Although effective this buffering system has limited capacity to counteract continuous generation of H+ equivalents by metabolism, ongoing transport of ions that alter the pH (H+ and HCO3−), or the presence of diseases that contribute to extracellular acidiﬁcation (inflammation, hypoxia, or ischemia). The mechanism of regulation of pHi carried out by transporters requires energy as H+ is transported against its electrochemical gradient. Thus, transporters use the inward Na+ gradient produced by the 3Na+/2K+-ATPase. Several proteins carry out this function being one of the most important Na+/H+ exchangers [1, 6, 7].
mechanisms of eukaryotic cell regulation. Mammalian MAPKs are activated by a wide variety of stimuli that include hormones, growth factors, inflammatory cytokines, osmotic shock, ischemic injury, and intracellular acidosis [35]. Upon activation, MAPKs phosphorylate NHE1. In particular, intracellular acidification leads to activation of the serine/threonine protein kinase Raf which then activates MEK (a MAPK kinase) that in turn activates extracellular signal-related kinase (ERK1/2) and ribosomal protein S6 kinase (p90rsk). ERK1/2 phosphorylates serine 770 and 771 while p90rsk phosphorylates serine 703 of the NHE1 protein (Figure 1) [36–42]. Moreover, NHE1 is phosphorylated by p160-Rho-associated kinase (p160ROCK) [43] and Nck-interacting kinase (NIK) [44]. The mechanisms by which protein phosphorylation enhances H+/Na+ exchange are unclear. However, it has been suggested that phosphorylation facilitates binding of carbonic anhydrase II, which in turn catalyses the hydration of CO2 to form HCO3− and H+ (Figure 1) [45]. NHE1 is also activated by calmodulin [46, 47], CHP1, CHP2 and tescalin (CHP3) [48–50]. Of note, the CHP-interacting region is flanked by two positively charged clusters that bind PIP2 in vitro which are important for NHE1 activity [51]. In addition, NHE1 binds to ERM cytoskeleton proteins which are important for signaling, cell migration, and apoptosis [52].

NHE1 is subject to inhibition. There is evidence that intracellular acidosis can negatively modulate NHE1 through phosphorylation by protein kinase B (PKB) [53] or dephosphorylation through protein phosphatase 2A (PP2A) [54]. This phosphorylation would interfere with Ca2+-calmodulin binding and could reduce the affinity for intracellular H+.

2. Role of NHE in Nociception

2.1. Inflammatory Pain. The role of NHE in pain processing has been studied recently. Blockade of peripheral NHE with nonselective NHE inhibitors such as amiloride and 5-(N,N-dimethyl)amiloride (DMA) increases flinching behavior in the capsaicin, serotonin, and formalin tests. In addition peripheral injection of 5-(N-ethyl-N-isopropyl)amiloride (EIPA), a selective NHE1 inhibitor, also increases nociception in the same models [55]. These studies suggest that peripheral NHE1 is the main responsible for the actions of the peripheral NHE inhibitors. Furthermore, spinal blockade of NHE1 with selective NHE1 inhibitors EIPA and zoniporide increases flinching behavior induced by formalin [56]. In line with these studies, in the rat skin-nerve preparation, amiloride increased pH-induced nociceptor (C-fibers) spike discharge [57]. Amiloride enhanced both the duration and the magnitude of the response. Authors attributed this effect to the blockade of NHE. NHE1 mRNA and protein are found in the dorsal root ganglia and lumbar dorsal horn [55]. Taken together, data suggest that NHE1 plays an important role as an intracellular pH sensor and as a protective mechanism in nociceptive neurons in acute inflammatory pain states (Figure 2). In addition, it has been shown that blockade of peripheral and spinal NHE1 promotes but not maintains long-lasting bilateral secondary allodynia and hyperalgesia.
### Table 1: Characteristics of the Na⁺/H⁺ exchanger (NHE) family.

| Common name (gene) | Distribution | Membrane Localization | Function | Pathophysiology |
|--------------------|--------------|------------------------|----------|----------------|
| NHE1 (SLC9A1)     | Ubiquitous   | Plasma membrane         | Cytosolic pH, cell volume, fluid secretion, cell shape, proliferation, migration | Ataxia, seizures, ischemia, reduced parotid gland secretion, pain |
| NHE2 (SLC9A2)     | Several tissues | Plasma membrane       | Fluid secretion | Loss of acid secretion, reduced parotid gland secretion |
| NHE3 (SLC9A3)     | Kidney, intestines | Plasma membrane       | Reabsorption of Na⁺ and HCO₃⁻ | Diarrhea, tubular proteinuria, hypertension |
| NHE4 (SLC9A4)     | Stomach, Kidney | Plasma membrane         | Cytosolic pH, fluid secretion | Impaired gastric acid secretion |
| NHE5 (SLC9A5)     | Brain, testis, spleen, and skeletal muscle | Plasma membrane       | Cytosolic pH | Pain |
| NHE6 (SLC9A6)     | Ubiquitous   | Endosomes               | Organellar pH | X-linked mental retardation, epilepsy, ataxia |
| NHE7 (SLC9A7)     | Ubiquitous   | Endosomes               | Organellar pH | Unknown |
| NHE8 (SLC9A8)     | Ubiquitous   | Endomembranes           | Organellar pH | Unknown |
| NHE9 (SLC9A9)     | Ubiquitous   | Endosomes               | Organellar pH | Attention-deficit hyperactivity disorder, autism-spectrum disorder |

2.2. Neuropathic Pain. The role of NHE1 in neuropathic pain has been less studied. Systemic injection of amiloride attenuated chronic constriction injury- and vincristine-induced neuropathic pain [61]. Authors attributed the observed antinoceceptive effects of amiloride to the inhibition of NHE with subsequent decrease in Ca²⁺ ions and oxidative stress. However, since they used doses of amiloride that also block acid sensing ion channels (ASICs) [62], it is likely that these effects may result from the blockade of ASICs instead of NHE. However, the final answer still needs confirmation.

Contrary to the results in inflammatory pain and in the skin-nerve preparation, other authors have reported that blockade of NHE1 by zoniporide reduces the amplitude of the compound action potential recorded from the dorsal root [63]. This study showed that blockade of NHE1 may reduce peripheral neuronal excitability by shifting fast Na⁺ channels into the inactivated state under physiological conditions. These actions may lead to antinoceceptive effects. However, the same group has reported that continuous intravenous infusion of zoniporide to rats and dogs for up to 1 month, but not for 2-weeks, produced peripheral neuropathies (axonal degeneration), in the spinal cord (dorsal funiculus), dorsal roots, and dorsal root ganglia [64]. Thus, more research is need on this point to clarify the role of NHE1 in neuropathic pain.

2.3. NHE in Nociceptive Neurons. NHE1 has been reported in dorsal root ganglia, dorsal spinal cord, and trigeminal neurons. NHE1 mRNA and protein expression are observed in dorsal root ganglia and dorsal spinal cord of rats [55]. Moreover, NHE5 protein is observed in spinal cord but not in dorsal root ganglia [55]. NHE1 is mainly expressed in the lamina I of the dorsal horn of the spinal cord and it colocalizes with peptide-rich sensory nerve fiber markers, substance P, and calcitonin gene-related peptide [56]. Others have found NHE1 in trigeminal ganglia [65] and colonic mucosa [59,66]. Furthermore, NHE1 transcript has been found in human dorsal root ganglion [67,68]. Data about the localization of NHE1 in neurons suggest that regulation of pHi may play a role in the nociceptive processing at peripheral and central sites (Figure 2).

2.4. NHE in Schwann Cells. NHE1 has been found in primary cultures of Schwann cells from rat sciatic nerve [69]. Authors found that NHE was moderately active at steady-state pHi. More recently, NHE3 has been found in Schwann cells on the laryngeal nerve [70]. Nerve fibers and nerve cell bodies of Schwann cells and satellite cells were surrounded by both proteins. It is likely that, as in other cells, NHE plays a role in Schwann cells regulating pHi. However, it has been reported that NHE may have a role in proliferation of Schwann cells as inhibition of NHE after addition of a mitogen significantly reduced the degree of mitosis [71].

2.5. NHE in Microglia. NHE1 is expressed in resting microglia [72]. Pharmacological inhibition of NHE1 activity acidifies primary or immortalized M4T.4 microglia in resting conditions and blockades pHi recovery capacity after experimental acidification [72–74]. These data suggest that NHE1

induced by formalin suggesting that NHE1 plays a role as a protective system in chronic pain as well [58]. Reinforcing this, NHE1 is downregulated from day 1 to 12 after formalin injection [58]. Similar results have been observed in biopsies from patients with ulcerative colitis and Crohn’s disease that present an inflammatory process and abdominal pain [59, 60].
plays a key role in maintaining pH in resting conditions and extruding H\(^+\) after acidosis in microglia. Activation of microglia by lipopolysaccharide does not change the expression of NHE1 but increases the activity to maintain pH. In addition, lipopolysaccharide increases the production of the superoxide radical (O\(_2\)\(^{•−}\)) in microglia while inhibition of NHE1 reduces microglial activation and proinflammatory response. These data suggest that NHE1 participates in the generation of O\(_2\)\(^{•−}\) through maintaining H\(^+\) homeostasis, thereby allowing for sustained NADPH oxidase complex activation in activated microglia [72]. Free radicals can subsequently lead to release of cytokotic proinflammatory cytokines. Since microglial activation and release of cytokines have been associated with inflammatory and neuropathic pain [75, 76], it has been suggested that NHE1 may be one of the mechanisms to increase microglial activity and sustain neuropathic pain [63, 64].

2.6. NHE in Astrocytes. Astrocytes play an important role throughout the central nervous system among others regulating pH [13]. Injury or stress to the central nervous system activates astrocytes, which then display an altered morphology and protein expression [77]. NHE1 protein has been found in astrocytes [78–81]. It seems that NHE1 is moderately active in basal conditions, but it can be activated by phosphorylation through tyrosine kinase (TK), ERK\(_{1/2}\), and p90\(^{rk}\), in astrocytes [78, 82, 83] further promoting extrusion of acid. Other substances like tumor necrosis factor-alpha (TNF\(\alpha\)), interferon-\(\gamma\), interleukin-1 beta (IL-1\(\beta\)), and hydrogen sulfide (H\(_2\)S) also produce intracellular acidification and activation of NHE in astrocytes. In contrast, cyclic GMP-inducing C-type natriuretic peptide and cyclic GMP inhibit NHE in astrocytes [84].

2.7. Role of NHE1 in Inflammatory Pain in Humans. Inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis have been associated with defects in homeostasis of cations as revealed by altered expression of several cation transporters [59, 85]. It is thought that these defects may be responsible for motility dysfunction, diarrhea, and pain commonly seen in patients with this type of diseases.
NHE1 plays an important role in cation homeostasis of the gastrointestinal tract [27]. There are consistent reports that NHE1 is reduced in ulcerative colitis and Crohn’s disease in humans [59, 60]. Authors suggest that this reduced expression may compromise recovery of acidic pH, and thus it may contribute to tissue necrosis and probably to pain [59, 66]. However, on the bases of the present data, we cannot discharge that other mechanisms might be contributing to produce the characteristic symptoms of the Crohn’s disease and ulcerative colitis.

On the contrary, NHE inhibition of human gut epithelial cells suppressed interleukin-8 production and activation of the p42/p44 mitogen-activated protein kinase and nuclear factor-kappaB. Furthermore, NHE inhibition ameliorated the course of inflammatory bowel disease in dextran sulfate-treated mice [86]. In support of this, NHE inhibitors may produce an anti-inflammatory effect by inhibiting the production of PGE₂ and the increase in COX-2 protein levels [87]. Differences could be due to the experimental approach used. However, more studies are needed in order to clarify this issue.

2.8. Perspectives and Conclusion. The role of NHE1 in nociception has recently been discovered. Data suggests that NHE1 plays a protective role in acute and chronic inflammatory pain. However, the role of NHE1 in neuropathic pain is controversial. Since NHE1 inhibitors produce an increase of inflammatory pain, the study of NHE1 inhibitors in neuropathic pain is difficult because models of neuropathic pain do not allow getting a graded level of allodynia in such way that blockade of NHE1 would allow assessing an increase in tactile allodynia. The development of NHE1 activators could help to solve the problem. The results observed in the acute and chronic model of inflammatory pain induced by formalin should be corroborated in other models of inflammatory pain. Particularly, the use of models related to chronic inflammatory conditions, in which acidification is a common feature, such as the injection of complete Freund’s adjuvant (CFA), moniodoacetate (MIA), or uric acid, is recommended. The use of knock-out mice as well as interference RNA directed against NHE1 and other members of the family would be helpful to delineate the participation of these proteins in the modulation of pain. The wide distribution of NHE1 could represent a challenge for drug development. Besides nociceptive neurons, NHE1 is found in heart and brain. Thus, activation of NHE1 may lead to side effects in those sites. However, the integrated study of the pH...
regulation involving NHE1 will definitely produce the basis to understand how nociceptive sensory neurons function in presence of the acidic conditions.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgments

V. Granados-Soto is a Visiting Professor at the Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. Support from CNPq is kindly acknowledged.

References

[1] M. Chesler, “Regulation and modulation of pH in the brain,” Physiological Reviews, vol. 83, no. 4, pp. 1183–1221, 2003.
[2] A. Roos and W. F. Boron, “Intracellular pH,” Physiological Reviews, vol. 61, no. 2, pp. 296–434, 1981.
[3] J. R. Casey, S. Grinstein, and J. Orlowski, “Sensors and regulators of intracellular pH,” Nature Reviews Molecular Cell Biology, vol. 11, no. 1, pp. 50–61, 2010.
[4] J. W. Deitmer and C. R. Rose, “pH regulation and proton signaling by glial cells,” Progress in Neurobiology, vol. 48, no. 2, pp. 73–103, 1996.
[5] A. Hulikova, A. L. Harris, R. D. Vaughan-Jones, and P. Swietach, “Acid-extrusion from tissue: the interplay between membrane transporters and pH buffers,” Current Pharmaceutical Design, vol. 18, no. 10, pp. 1331–1337, 2012.
[6] L. K. Putney, S. P. Denker, and D. L. Barber, “The changing face of the Na+/H+ exchanger, NHE1: structure, regulation, and cellular actions,” Annual Review of Pharmacology and Toxicology, vol. 42, pp. 527–552, 2002.
[7] S. F. Pedersen, M. E. O’Donnell, S. E. Anderson, and P. M. Cala, “Physiology and pathophysiology of Na+/H+ exchange and Na+–K+–2Cl– cotransport in the heart, brain, and blood,” American Journal of Physiology, vol. 291, no. 1, pp. R1–R25, 2006.
[8] J. Pouysségur, “Molecular biology and hormonal regulation of vertebrate Na+/H+ exchanger isoforms,” Renal Physiology and Biochemistry, vol. 17, no. 3-4, pp. 190–193, 1994.
[9] J. Orlowski and S. Grinstein, “Na+/H+ exchangers of mammalian cells,” Journal of Biological Chemistry, vol. 272, no. 36, pp. 22373–22376, 1997.
[10] J. Orlowski and S. Grinstein, “Diversity of the mammalian sodium/proton exchanger SLC9 gene family,” Pfugers Arch European Journal of Physiology, vol. 447, no. 5, pp. 549–565, 2004.
[11] S. F. Pedersen and P. M. Cala, “Comparative biology of the ubiquitous Na+/H+ exchanger, NHE1: lessons from erythrocytes,” Journal of Experimental Zoology Part A, vol. 301, no. 7, pp. 569–578, 2004.
[12] E. R. Slepkov, J. K. Rainey, B. D. Sykes, and L. Fliegel, “Structural and functional analysis of the Na+/H+ exchanger,” Biochemical Journal, vol. 401, no. 3, pp. 623–633, 2007.
[13] M. Obara, M. Szeliga, and J. Albrecht, “Regulation of pH in the mammalian central nervous system under normal and pathological conditions: facts and hypotheses,” Neurochemistry International, vol. 52, no. 6, pp. 905–919, 2008.
[14] R. A. Cardone, V. Casavola, and S. J. Reshkin, “The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis,” Nature Reviews Cancer, vol. 5, no. 10, pp. 786–795, 2005.
[15] M. Avkiran, “Protection of the ischaemic myocardium by Na+/H+ exchange inhibitors: potential mechanisms of action,” Basic Research in Cardiology, vol. 96, no. 4, pp. 306–311, 2001.
[16] L. Fliegel, “Regulation of myocardial Na+/H+ exchanger activity,” Basic Research in Cardiology, vol. 96, no. 4, pp. 301–305, 2001.
[17] K. Imahashi, F. Mraiche, C. Steenbergen, E. Murphy, and L. Fliegel, “Overexpression of the Na+/H+ exchanger and ischemia-reperfusion injury in the myocardium,” American Journal of Physiology, vol. 292, no. 5, pp. H2237–H2247, 2007.
[18] A. R. Cook, S. C. Bardswell, S. Pretheshan et al., “Paradoxical resistance to myocardial ischemia and age-related cardiomyopathy in NHE1 transgenic mice: a role for ER stress?” Journal of Molecular and Cellular Cardiology, vol. 46, no. 2, pp. 225–233, 2009.
[19] F. Mraiche, C. S. Wagg, G. D. Lopaschuk, and L. Fliegel, “Elevated levels of activated NHE1 protect the myocardium and improve metabolism following ischemia/reperfusion injury,” Journal of Molecular and Cellular Cardiology, vol. 50, no. 1, pp. 157–164, 2011.
[20] C. C. Aickin and R. C. Thomas, “An investigation of the ionic mechanism of intracellular pH regulation in mouse soleus muscle fibres,” Journal of Physiology, vol. 273, no. 1, pp. 295–316, 1977.
[21] C. Sardet, A. Franchi, and J. Pouysségur, “Molecular cloning of the growth-factor-activatable human Na+/H+ antiporter,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 53, no. 2, pp. 1011–1018, 1988.
[22] C. Sardet, A. Franchi, and J. Pouysségur, “Molecular cloning, primary structure, and expression of the human growth factor-activatable Na+/H+ antiporter,” Cell, vol. 56, no. 2, pp. 271–280, 1989.
[23] G. Kemp, H. Young, and L. Fliegel, “Structure and function of the human Na+/H+ exchanger isoform,” Channels, vol. 2, no. 5, pp. 329–336, 2008.
[24] D. Biemesderfer, J. Pizzonia, A. Abu-Alfa et al., “NHE3: a Na+/H+ exchanger isoform of renal brush border,” American Journal of Physiology, vol. 265, no. 5, pp. F736–F742, 1993.
[25] C. Bookstein, M. W. Musch, A. DePaoli et al., “A unique sodium-hydrogen exchange isoform (NHE-4) of the inner medulla of the rat kidney is induced by hyperosmolarity,” Journal of Biological Chemistry, vol. 269, no. 47, pp. 29704–29709, 1994.
[26] W. A. Hoogerwerf, S. C. Tsao, O. Devuyst et al., “NHE2 and NHE3 are human and rabbit intestinal brush-border proteins,” American Journal of Physiology, vol. 270, no. 1, pp. G29–G41, 1996.
[27] N. C. Zachos, M. Tse, and M. Donowitz, “Molecular physiology of intestinal Na+/H+ exchange,” Annual Review of Physiology, vol. 67, pp. 411–443, 2005.
[28] C. A. Klanke, Yan Ru Su, D. F. Callen et al., “Molecular cloning and physical and genetic mapping of a novel human Na+/H+ exchanger (NHE5/SLC9AS5) to chromosome 16q22.1,” Genomics, vol. 25, no. 3, pp. 615–622, 1995.
[29] N. R. Baird, J. Orlowski, E. Z. Szabó et al., “Molecular cloning, genomic organization, and functional expression of Na+/H+ exchanger isoform 5 (NHE5) from human brain,” Journal of Biological Chemistry, vol. 274, no. 7, pp. 4377–4382, 1999.
[30] E. Miyazaki, M. Sakaguchi, S. Wakabayashi, M. Shigekawa, and K. Mihara, “NHE6 protein possesses a signal peptide destined for endoplasmic reticulum membrane and localizes in secretory organelles of the cell,” Journal of Biological Chemistry, vol. 276, no. 52, pp. 49221–49227, 2001.

[31] N. Fukura, R. Ohgaki, M. Matsushita, N. Nakamura, K. Mitsui, and H. Kanazawa, “A membrane-proximal region in the C-terminal tail of NHE7 is required for its distribution in the trans-golgi network, distinct from NHE6 localization at endosomes,” Journal of Membrane Biology, vol. 234, no. 3, pp. 149–158, 2010.

[32] S. Wakabayashi, T. Pang, X. Su, and M. Shigekawa, “A novel topology model of the human Na’/H’ exchanger isoform 1,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 7942–7949, 2000.

[33] R. Beliveau, M. Demeule, and M. Potier, “Molecular size of the Na’-H’ antiport in renal brush border membranes, as estimated by radiation inactivation,” Biochemical and Biophysical Research Communications, vol. 152, no. 1, pp. 484–489, 1988.

[34] P. Fafournoux, J. Noël, and J. Pouyssegur, “Evidence that Na’/H’ exchanger isoforms NHE1 and NHE3 exist as stable dimers in membranes with a high degree of specificity for homodimers,” Journal of Biological Chemistry, vol. 269, no. 4, pp. 2589–2596, 1994.

[35] M. Krishna and H. Narang, “The complexity of mitogen-activated protein kinases (MAPKs) made simple,” Cellular and Molecular Life Sciences, vol. 65, no. 22, pp. 3525–3544, 2008.

[36] H. Wang, N. L. C. L. Silva, P. A. Lucchesi et al., “Phosphorylation and regulation of the Na’/H’ exchanger through mitogen-activated protein kinase,” Biochemistry, vol. 36, no. 30, pp. 9151–9158, 1997.

[37] A. N. Moor and L. Fliegel, “Protein kinase-mediated regulation of the Na’/H’ exchanger in the rat myocardium by mitogen-activated protein kinase-dependent pathways,” Journal of Biological Chemistry, vol. 274, no. 33, pp. 22985–22992, 1999.

[38] A. N. Moor, X. T. Gan, M. Karmazyn, and L. Fliegel, “Activation of Na’/H’ exchanger-directed protein kinases in the ischemic and ischemic-reperfused rat myocardium,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16113–16122, 2001.

[39] A. R. Khaled, A. N. Moor, A. Li et al., “Trophic factor withdrawal: p38 mitogen-activated protein kinase activates NHE1, which induces intracellular alkalization,” Molecular and Cellular Biology, vol. 21, no. 22, pp. 7545–7557, 2001.

[40] R. S. Haworth, C. McCann, A. K. Snabaitis, N. A. Roberts, and M. Avkiran, “Stimulation of the plasma membrane Na’/H’ exchanger NHE1 by sustained intracellular acidosis. Evidence for a novel mechanism mediated by the ERK pathway,” Journal of Biological Chemistry, vol. 278, no. 34, pp. 31676–31684, 2003.

[41] J. Luo and D. Sun, “Physiology and pathophysiology of Na’/H’ exchange isoform 1 in the central nervous system,” Current Neurovascular Research, vol. 4, no. 3, pp. 205–215, 2007.

[42] P. Karki, E. Coccaro, and L. Fliegel, “Sustained intracellular acidosis activates the myocardial Na’/H’ exchanger independent of amino acid Ser703 and p90rsk,” Biochimica et Biophysica Acta, vol. 1798, no. 8, pp. 1565–1576, 2010.

[43] T. Tominaga, T. Ishizaki, S. Narumiya, and D. L. Barber, “p160ROCK mediates RhoA activation of Na-H exchange,” The EMBO Journal, vol. 17, no. 16, pp. 4712–4722, 1998.

[44] W. Yan, K. Nehrke, J. Choi, and D. L. Barber, “Nck-interacting kinase (NIK) phosphorylates the Na’-H’ exchanger NHE1 and regulates NHE1 activation by platelet-derived growth factor,” Journal of Biological Chemistry, vol. 276, no. 33, pp. 31349–31356, 2001.

[45] X. Li, B. Alvarez, J. R. Casey, R. A. F. Reithmeier, and L. Fliegel, “Carboxy anhydrase II binds to and enhances activity of the Na’/H’ exchanger,” Journal of Biological Chemistry, vol. 277, no. 39, pp. 36085–36091, 2002.

[46] B. Bertrand, S. Wakabayashi, T. Ikeda, J. Pouyssegur, and M. Shigekawa, “The Na’/H’ exchanger isoform 1 (NHE1) is a novel member of the calmodulin-binding proteins. Identification and characterization of calmodulin-binding sites,” Journal of Biological Chemistry, vol. 269, no. 18, pp. 13703–13709, 1994.

[47] S. Wakabayashi, T. Ikeda, T. Iwamoto, S. Shigekawa, and M. Shigekawa, “Calmodulin-binding autoinhibitory domain controls ‘pH-sensing’ in the Na’/H’ exchanger NHE1 through sequence-specific interaction,” Biochemistry, vol. 36, no. 42, pp. 12854–12861, 1997.

[48] T. Pang, X. Su, S. Wakabayashi, and M. Shigekawa, “Calcineurin homologous protein as an essential cofactor for Na’/H’ exchangers,” Journal of Biological Chemistry, vol. 276, no. 20, pp. 17367–17372, 2001.

[49] T. Pang, S. Wakabayashi, and M. Shigekawa, “Expression of calcineurin B homologous protein 2 protects serum deprivation-induced cell death by serum-independent activation of Na’/H’ exchanger,” Journal of Biological Chemistry, vol. 277, no. 46, pp. 43771–43777, 2002.

[50] H. C. Zaun, A. Shrier, and J. Orlowski, “Calcineurin B homologous protein 3 promotes the biosynthetic maturation, cell surface stability, and optimal transport of the Na’/H’ exchanger NHE1 isoform,” Journal of Biological Chemistry, vol. 283, no. 18, pp. 12456–12467, 2008.

[51] O. Aharonovitz, H. C. Zaun, T. Balla, J. D. York, J. Orlowski, and S. Grinstein, “Intracellular pH regulation by Na’/H’ exchange requires phosphatidylinositol 4,5-bisphosphate,” Journal of Cell Biology, vol. 150, no. 1, pp. 213–224, 2000.

[52] S. P. Denker, D. C. Huang, J. Orlowski, H. Furthmayr, and D. L. Barber, “Direct binding of the Na-H exchanger NHE1 to ERM proteins regulates the cortical cytoskeleton and cell shape independently of H’ translocation,” Molecular Cell, vol. 6, no. 6, pp. 1425–1436, 2000.

[53] A. K. Snabaitis, F. Cuello, and M. Avkiran, “Protein kinase B/Akt phosphorylates and inhibits the cardiac Na’/H’ Exchanger NHE1,” Circulation Research, vol. 103, no. 8, pp. 881–890, 2008.

[54] A. K. Snabaitis, R. D’Mello, S. Dashnyam, and M. Avkiran, “A novel role for protein phosphatase 2A in receptor-mediated regulation of the cardiac sarcolemmal Na’/H’ exchanger NHE1,” Journal of Biological Chemistry, vol. 281, no. 29, pp. 20252–20262, 2006.

[55] H. I. Rocha-González, G. Castañeda-Coral, C. I. Araiza-Saldaña et al., “Identification of the Na’/H’ exchanger 1 in dorsal root ganglion and spinal cord: its possible role in inflammatory nociception,” Neuroscience, vol. 160, no. 1, pp. 156–164, 2009.

[56] G. Castañeda-Coral, H. I. Rocha-González, B. Godinez-Chaparro, J. M. Jiménez-Andrade, and V. Granados-Soto, “Role of the spinal Na’/H’ exchanger in formalin-induced nociception,” Neuroscience Letters, vol. 501, no. 1, pp. 4–9, 2011.

[57] K. H. Steen, H. Wegner, and P. W. Reeh, “The pH response of rat cutaneous nociceptors correlates with extracellular [Na’] and is increased under amiloride,” European Journal of Neuroscience, vol. 11, no. 8, pp. 2783–2792, 1999.
C. N. Liu and C. J. Somps, “Blockade of peripheral and spinal Na+/H+ exchanger increases formalin-induced long-lasting mechanical allodynia and hyperalgesia in rats,” Brain Research, vol. 1475, pp. 19–30, 2012.

I. Khan, I. Siddique, F. M. Al-Awadi, and K. Mohan, “Role of Na+/H+ exchanger isoform-1 in human inflammatory bowel disease,” Canadian Journal of Gastroenterology, vol. 17, no. 1, pp. 31–36, 2003.

I. Siddique and I. Khan, “Mechanism of regulation of Na-H exchanger in inflammatory bowel disease: role of TLR-4 signaling mechanism,” Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1656–1662, 2011.

A. Muthuraman, A. S. Jaggi, N. Singh, and D. Singh, “Ameliorative effects of amiloride and pralidoxime in chronic constriction injury and vincristine induced painful neuropathy in rats,” European Journal of Pharmacology, vol. 587, no. 1–3, pp. 104–111, 2008.

J. Ferreira, A. R. S. Santos, and J. B. Calixto, “Antinociception produced by systemic, spinal and supraspinal administration of amiloride in mice,” Life Sciences, vol. 65, no. 10, pp. 1059–1066, 1999.

C. N. Liu and C. J. Somps, “Na+H+ exchanger-1 inhibitors reduce neuronal excitability and alter Na+ channel inactivation properties in rat primary sensory neurons,” Toxicological Sciences, vol. 103, no. 2, pp. 346–353, 2008.

J. C. Pettersen, L. Chouinard, R. L. Kerlin et al., “Neurotoxic effects of zoniporide: a selective inhibitor of the Na+/H+ exchanger isoform 1,” Toxicologic Pathology, vol. 36, no. 4, pp. 608–619, 2008.

S. M. Hwang, N. Y. Koo, M. Jin et al., “Intracellular acidification is associated with changes in free cytosolic calcium and inhibition of action potentials in rat trigeminal ganglion,” Journal of Biological Chemistry, vol. 286, no. 3, pp. 1719–1729, 2011.

I. Khan, F. M. Al-Awadi, and H. Abul, “Colitis-induced changes in the expression of the Na+/H+ exchanger isoform NHE-1,” Journal of Pharmacology and Experimental Therapeutics, vol. 285, no. 2, pp. 869–875, 1998.

J. H. Shin, W. Namkung, C. H. Kim et al., “Expression of Na+/H+ exchanger isoforms in normal human nasal epithelial cells and functional activity of Na+/H+ exchanger 1 in intracellular pH regulation,” Acta Oto-Laryngologica, vol. 125, no. 3, pp. 286–292, 2005.

BioGPS, http://biogps.org/#goto=welcome.

N. L. Nakhoul, S. Abdulnour-Nakhoul, R. N. Khuri, E. M. Lieberman, and P. T. Hargittai, “Intracellular pH regulation in rat Schwann cells,” Glia, vol. 10, no. 3, pp. 155–164, 1994.

Y. Yamamoto and K. Taniguchi, “Distribution of pH regulators in the rat laryngeal nerve: the spatial relationship between Na+/HCO3- cotransporters and Na+/H+ exchanger type 3,” Neuroscience Letters, vol. 368, no. 2, pp. 127–129, 2004.

R. D. Saunders, Y. W. Brandon, and G. H. De Vries, “Role of intracellular pH in the axolemma- and myelin-induced proliferation of Schwann cells,” Journal of Neurochemistry, vol. 52, no. 5, pp. 1576–1581, 1989.

Y. Liu, D. B. Kintner, V. Chanana et al., “Activation of microglia depends on Na+/H+ exchange-mediated H+ homeostasis,” Journal of Neuroscience, vol. 30, no. 45, pp. 15210–15220, 2010.

L. Faff, C. Ohlemeyer, and H. Kettenmann, “Intracellular pH regulation in cultured microglial cell from mouse brain,” Journal of Neuroscience Research, vol. 46, no. 3, pp. 294–304, 1996.

Y. Shi, V. Chanana, J. J. Watters, P. Ferrazzano, and D. Sun, “Role of sodium/hydrogen exchanger isoform 1 in microglial activation and proinflammatory responses in ischemic brains,” Journal of Neurochemistry, vol. 119, no. 1, pp. 124–135, 2011.

R. W. Colburn, A. J. Rickman, and J. A. Deleo, “The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior,” Experimental Neurology, vol. 157, no. 2, pp. 289–304, 1999.

S. X. Jin, Z. Y. Zhuang, C. J. Woolf, and R. R. Ji, “p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain,” Journal of Neuroscience, vol. 23, no. 10, pp. 4017–4022, 2003.

M. D. Laird, J. R. Vender, and K. M. Dhandapani, “Opposing roles for reactive astrocytes following traumatic brain injury,” Neurosignals, vol. 16, no. 2-3, pp. 154–164, 2008.

D. J. Benos, S. McPherson, B. H. Hahn, M. A. Chaikin, and E. N. Benveniste, “Cytokines and HIV envelope glycoprotein gp120 stimulate Na+/H+ exchange in astrocytes,” Journal of Biological Chemistry, vol. 269, no. 19, pp. 13811–13816, 1994.

M. O. Beversee, M. Apkon, and W. F. Boron, “Intracellular pH regulation in cultured astrocytes from rat hippocampus. II. Electrogenic Na/HCO3- cotransport,” Journal of General Physiology, vol. 110, no. 4, pp. 467–483, 1997.

J. H. Pizzonia, B. R. Ransom, and C. A. Pappas, “Characterization of Na+/H+ exchange activity in cultured rat hippocampal astrocytes,” Journal of Neuroscience Research, vol. 44, no. 2, pp. 191–198, 1996.

P. Cengiz, N. Kleman, K. Uluc et al., “Inhibition of Na+/H+ exchanger isoform 1 is neuroprotective in neonatal hypoxic ischemic brain injury,” Antioxidants and Redox Signaling, vol. 14, no. 10, pp. 1803–1813, 2011.

D. B. Kintner, A. Look, G. E. Shull, and D. Sun, “Stimulation of astrocyte Na+/H+ exchange activity in response to in vitro ischemia depends in part on activation of ERK1/2,” American Journal of Physiology, vol. 289, no. 4, pp. C934–C945, 2005.

A. Mandal, M. Shahidullah, N. A. Delamere, and M. A. Terán, “Elevated hydrostatic pressure activates sodium/hydrogen exchanger-1 in rat optic nerve head astrocytes,” American Journal of Physiology, vol. 297, no. 1, pp. C111–C120, 2009.

R. M. Touyz, S. Picardi, E. L. Schiffrin, and C. F. Deschepper, “Cyclic GMP inhibits a pharmacologically distinct Na+/H+ exchanger variant in cultured rat astrocytes via an extracellular site of action,” Journal of Neurochemistry, vol. 68, no. 4, pp. 1451–1461, 1997.

I. Siddique, F. Hasan, and I. Khan, “Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5-aminosaliclyc treatment,” Scandinavian Journal of Gastroenterology, vol. 44, no. 1, pp. 56–64, 2009.

Z. H. Németh, E. A. Deitch, C. Szabó et al., “Na+/H+ exchanger blockade inhibits enterocyte inflammatory response and protects against colitis,” American Journal of Physiology, vol. 283, no. 1, pp. G122–G132, 2002.

F. Kamachi, S. B. Hyun, N. Hirasawa, and K. Ohuchi, “Inhibition of lipopolysaccharide-induced prostaglandin E2 production and inflammation by the Na+/H+ exchanger inhibitors,” Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 1, pp. 345–352, 2007.